Business Context and Reporting Period
Company: Illumina, Inc. (ILMN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 29, 2024 (52 weeks)
Business Overview: Illumina is a global leader in sequencing- and array-based solutions for genetic and genomic analysis, serving research, clinical, and applied markets. The company operates as a single reportable segment, "Core Illumina," following the June 24, 2024, spin-off of GRAIL, Inc. into an independent public company. Illumina retained approximately 14.5% of GRAIL's common stock post-spin-off.
Key Financial Metrics
| Metric (in millions, except per share) | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $4,372 | $4,504 | (3)% |
| Gross Profit | $2,861 | $2,744 | 4% |
| Gross Margin | 65.4% | 60.9% | +450 bps |
| Operating Loss | $(833) | $(1,069) | Improvement |
| Net Loss | $(1,223) | $(1,161) | (5)% |
| Loss Per Share (Diluted) | $(7.69) | $(7.34) | (5)% |
| Operating Cash Flow | $837 | $478 | 75% |
| Cash & Equivalents (End of Period) | $1,127 | $1,048 | 7% |
| Total Debt (Principal) | $2,000 | $1,500 | N/A |
Note: Total Debt includes $500M 2025 Notes, $500M 2026 Notes, $500M 2027 Notes, and $500M 2031 Notes. No borrowings were outstanding under the Revolving Credit Facility.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 3% to $4.4 billion. This was driven by a 29% drop in instrument revenue ($501M vs. $706M) due to fewer shipments of high-throughput instruments following the 2023 NovaSeq X launch. This was partially offset by a 2% increase in consumables revenue ($3.17B vs. $3.11B).
- Margin Expansion: Gross margin improved to 65.4% from 60.9%, driven by operational excellence initiatives, a favorable shift in revenue mix toward consumables, and reduced warranty costs.
- Impairment Charges: The company recorded $1.889 billion in goodwill and intangible impairment charges in 2024, compared to $827 million in 2023. This included a $1.466 billion goodwill impairment and $420 million IPR&D impairment related to GRAIL prior to the spin-off.
- Legal Contingency Gain: A $456 million gain was recognized in 2024 (vs. $20M expense in 2023) due to the European Commission withdrawing a previously imposed fine related to the GRAIL acquisition.
- GRAIL Spin-Off: The separation of GRAIL resulted in the deconsolidation of $968 million in cash and $2.7 billion in net assets. GRAIL revenue and expenses are no longer consolidated after June 24, 2024.
Guidance, Outlook, and Risks
Management Outlook: Management expects to continue focusing on operational excellence and cost reduction to accelerate progress toward higher margins. The company aims to return to revenue growth in 2025. Macroeconomic factors, including inflation and exchange rate fluctuations, are expected to continue impacting sales.
Key Risks and Contingencies:
- China Regulatory Action: On February 4, 2025, China's Ministry of Commerce added Illumina to its "List of Unreliable Entities." Potential penalties include fines, trade restrictions, or prohibitions on business in China. Revenue from Greater China was $308 million in 2024.
- Legal Proceedings: Multiple shareholder derivative lawsuits and securities class actions remain pending regarding the GRAIL acquisition and related disclosures. An SEC investigation is ongoing.
- Regulatory Changes: New FDA rules regarding Laboratory Developed Tests (LDTs) could impact the commercialization of certain products and require additional regulatory approvals.
- Contingent Value Rights (CVRs): Illumina remains the obligor on CVRs issued to GRAIL shareholders, with a fair value of $71 million as of year-end. Future payments depend on GRAIL's revenue performance.
Investor Verification Checklist
- China Exposure: Verify the specific impact of the "Unreliable Entities" designation on future shipments and revenue in the Greater China region ($308M in 2024).
- Instrument Sales Cycle: Monitor the recovery of instrument revenue, which dropped 29% in 2024, and the adoption rate of the NovaSeq X platform.
- Legal Liabilities: Track the status of pending securities class actions and shareholder derivative suits related to the GRAIL transaction.
- GRAIL Investment: Review the performance of the retained 14.5% stake in GRAIL, which incurred a $309 million unrealized loss in 2024.
- Debt Maturities: Confirm the company's ability to service $500 million in term notes maturing in December 2025.